- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02268149
Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects
October 16, 2014 updated by: Boehringer Ingelheim
The Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Male Subjects (A Randomized, Double-blind, Placebo-controlled, Two Period, Two-way Cross-over Study)
Study to evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of prednisone
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Written informed consent signed and dated prior to participation into the study
- All participants in the study should be healthy males, aged 18-50 years old inclusive
- All participants should be within (+- 20%) of their ideal body weight (Broca-Index)
- Non-smokers (subject who have never smoked) or ex-smoker for at least one year with a smoking history, no greater than five pack-years (1 pack year = 20 cigarettes per day for 1 year)
- Ability to comply with the concomitant therapy restrictions as detailed in Clinical Trial Protocol (CTP)
- Subjects will be off all prescription drugs. O.T.C. drugs must be discontinued for at least two weeks prior to participation in the study. If throughout the study, subjects need any O.T.C. medication, the investigator will call the clinical monitor and this will be reviewed on a case-by-case basis. Restrictions for different medications are described in CTP
- Subjects will have no evidence of clinically relevant concomitant disease based upon complete medical history, full physical examination, chest-x-ray (if not done in previous 6 months), ECG and clinical laboratory tests
Exclusion Criteria:
- Viral respiratory tract infection or a respiratory tract infection within the six weeks preceding dosing with study medication
- Small or difficult to locate arm or hand veins that would impair the clinicians ability to draw blood samples or to place a venous catheter
- Subjects with a known drug or alcohol dependence (absence of dependency for 10 years) or who drink more than 60 g of alcohol per day, history of significant allergic reactions to drugs or sensitivity to aspirin or positive drug screen
- Use of investigational new drug in the preceding month or six half-lives (whichever is greater) prior to the first screen at Visit 1
- Donation of blood during the month preceding Visit 1
- Subjects receiving hyposensitization therapy who are not on a stable dose for the last three months before Visit 1
- Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Subjects with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- Subjects with known history of orthostatic hypotension, fainting spells or blackouts
- Subjects with chronic or relevant acute infections
- Subjects with history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Subjects with eosinophilia > 7 %
- Subjects who received any other drugs, which might influence the results of the trial during the weeks prior to dosing with study medication
- Subjects who participated in excessive physical activities (e.g. competitive sports) within the last week before dosing with study medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIIL 284 BS + Prednisone
BIIL 284 BS 9 days; prednisone 2 single doses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC (Area under the concentration-time curve of the analyte in plasma)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
Cmax (Maximum measured concentration of the analyte in plasma)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
tmax (Time from dosing to the maximum concentration of the analyte in plasma)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
t½ (Terminal half-life of the analyte in plasma)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
MRTtot (total Mean residence time)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
CLtot/F (Total clearance of the analyte in plasma after oral administration)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
Vz/F (Apparent volume of distribution of the analyte during the terminal phase)
Time Frame: up to 72 hours post dose
|
up to 72 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with adverse events
Time Frame: up to 53 days
|
up to 53 days
|
Changes in immunomodulatory assessed by T-cell proliferation
Time Frame: predose, 4 hours post dose
|
predose, 4 hours post dose
|
Changes in Interleukin-2 (IL-2) levels
Time Frame: predose, 4 hours post dose
|
predose, 4 hours post dose
|
Changes in Interferon gamma (IFNy) levels
Time Frame: predose, 4 hours post dose
|
predose, 4 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2000
Primary Completion (Actual)
July 1, 2000
Study Registration Dates
First Submitted
October 16, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (Estimate)
October 20, 2014
Study Record Updates
Last Update Posted (Estimate)
October 20, 2014
Last Update Submitted That Met QC Criteria
October 16, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 543.24
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States